David Taber
Impact in
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
Papers in ⓘ
-
- Lung Cancer Treatments and Mutations 8
- Renal cell carcinoma treatment 5
- Oncology 14
- Colorectal Cancer Treatments and Studies 6
- Peptidase Inhibition and Analysis 3
- Co-authors
- Walter M. Stadler (8 shared papers)Everett E. Vokes (13 shared papers)Nicholas J. Vogelzang (5 shared papers)Hedy L. Kindler (7 shared papers)Theodore Karrison (3 shared papers)Mark Kozloff (4 shared papers)D. A. Singh (3 shared papers)Sreenivasa Nattam (2 shared papers)
- Journals
- Journal of Clinical Oncology (10 papers)Journal of the American Oil Chemists Society (4 papers)Investigational New Drugs (3 papers)Journal of the American Chemical Society (2 papers)Journal of Thoracic Oncology (1 paper)
- Partner nations
- United States
In The Last Decade
David Taber
28 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 86
- Oncology 643
- Cancer Research 280
- Pulmonary and Respiratory Medicine 475
- Otorhinolaryngology 36
- Molecular Biology 445
Countries citing papers authored by David Taber
This map shows the geographic impact of David Taber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Taber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Taber more than expected).
Fields of papers citing papers by David Taber
This network shows the impact of papers produced by David Taber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Taber. The network helps show where David Taber may publish in the future.
Co-authors
The 25 scholars most cited alongside David Taber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 360 | |
| 2 | 2000 | 167 | |
| 3 | 2012 | 144 | |
| 4 | 2000 | 121 | |
| 5 | 2003 | 114 | |
| 6 | 2009 | 59 | |
| 7 | 2011 | 43 | |
| 8 | 2008 | 19 | |
| 9 | 2005 | 14 | |
| 10 | 2008 | 14 | |
| 11 | 1954 | 14 | |
| 12 | 2006 | 10 | |
| 13 | 1956 | 10 | |
| 14 | 2012 | 8 | |
| 15 | 1972 | 7 | |
| 16 | 2005 | 6 | |
| 17 | 2009 | 5 | |
| 18 | 1967 | 5 | |
| 19 | 1971 | 5 | |
| 20 | Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. | 1998 | 5 |
About David Taber
David Taber is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Organic Chemistry, Surgery and Molecular Biology, having authored 28 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (6 papers), Renal cell carcinoma treatment (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers), Antimicrobial agents and applications (3 papers), Cancer Genomics and Diagnostics (3 papers), Peptidase Inhibition and Analysis (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). The work is most often cited by research in Oncology (643 citations), Cancer Research (280 citations), Pulmonary and Respiratory Medicine (475 citations), Otorhinolaryngology (36 citations) and Molecular Biology (445 citations). David Taber has collaborated with scholars based in United States. Frequent co-authors include Walter M. Stadler, Everett E. Vokes, Nicholas J. Vogelzang, Hedy L. Kindler, Theodore Karrison, Mark Kozloff, D. A. Singh, Sreenivasa Nattam, Gregory Friberg and Gershon Y. Locker. Their work appears in journals such as Journal of Clinical Oncology, Journal of the American Oil Chemists Society, Investigational New Drugs, Journal of the American Chemical Society and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.